Mineralys Therapeutics Inc (MLYS)

Jun 04, 2025

BNP Paribas Financial Markets Buys Shares of 3,895 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Jun 04, 2025

Jun 03, 2025

Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha

Jun 03, 2025

Jun 03, 2025

ProShare Advisors LLC Takes Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Jun 03, 2025

Jun 01, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Deutsche Bank AG - Defense World

Jun 01, 2025

May 28, 2025

Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat - MSN

May 28, 2025

May 28, 2025

Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting - MSN

May 28, 2025

May 27, 2025

Mineralys announces late-breaking presentation of data from Launch-HTN trial - Yahoo Finance

May 27, 2025

May 26, 2025

Buy Rating for Mineralys Therapeutics: Strong Clinical Results and Growth Prospects Highlight Significant Upside Potential - TipRanks

May 26, 2025

May 26, 2025

Mineralys reports outcomes from trial of lorundrostat for hypertension - Yahoo Finance

May 26, 2025

May 26, 2025

MLYS: Promising Phase 3 Results for Hypertension Treatment | MLYS Stock News - GuruFocus

May 26, 2025

May 24, 2025

Northern Trust Corp Purchases 1,688 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

May 24, 2025

May 24, 2025

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) - The Manila Times

May 24, 2025

May 24, 2025

Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension - Nasdaq

May 24, 2025

May 24, 2025

These 3 Artificial Intelligence (AI) Stocks Look Cheap Right Now - The Globe and Mail

May 24, 2025

May 24, 2025

Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 - marketscreener.com

May 24, 2025

May 24, 2025

Mineralys Therapeutics Announces Late-Breaking Presentation - GlobeNewswire

May 24, 2025

May 24, 2025

Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan

May 24, 2025

May 22, 2025

Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

May 22, 2025

May 22, 2025

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going - sharewise

May 22, 2025

May 21, 2025

Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com Australia

May 21, 2025

May 20, 2025

Mineralys to present lorundrostat trial data at ESH 2025 By Investing.com - Investing.com South Africa

May 20, 2025

May 20, 2025

Mineralys Announces Late-Breaking Presentation Of Phase 3 Launch-HTN Trial - marketscreener.com

May 20, 2025

May 20, 2025

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection - The Manila Times

May 20, 2025

May 20, 2025

Breakthrough Phase 3 Trial Data: New Drug Takes Aim at Treatment-Resistant Hypertension Crisis - Stock Titan

May 20, 2025

May 19, 2025

Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM - MSN

May 19, 2025

May 19, 2025

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - Yahoo Finance

May 19, 2025

May 19, 2025

Balyasny Asset Management L.P. Takes $219,000 Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

May 19, 2025

May 18, 2025

Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MSN

May 18, 2025

May 18, 2025

Dimensional Fund Advisors LP Acquires Shares of 16,412 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

May 18, 2025

May 16, 2025

Mineralys plans NDA submission for lorundrostat following pivotal hypertension data and $201M equity raise - MSN

May 16, 2025

May 16, 2025

Insider Sell Alert: David Rodman Sells Shares of Mineralys Thera - GuruFocus

May 16, 2025

May 16, 2025

HC Wainwright Issues Positive Estimate for MLYS Earnings - Defense World

May 16, 2025

May 15, 2025

Mineralys Therapeutics’ Earnings Call: Positive Outlook Amid Challenges - TipRanks

May 15, 2025

May 15, 2025

Mineralys Therapeutics (NASDAQ:MLYS) Earns “Buy” Rating from HC Wainwright - Defense World

May 15, 2025

May 15, 2025

Transcript : Mineralys Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com

May 15, 2025

May 14, 2025

Elevatebio names Ger Brophy interim CEO - biocentury.com

May 14, 2025

May 14, 2025

Guggenheim Adjusts Price Target for Mineralys Therapeutics (MLYS - GuruFocus

May 14, 2025

May 14, 2025

Guggenheim Adjusts Price Target for Mineralys Therapeutics (MLYS) | MLYS Stock News - GuruFocus

May 14, 2025

May 13, 2025

Mineralys Therapeutics to Present at Bank of America Health Care Conference - MSN

May 13, 2025

May 13, 2025

Positive Buy Rating for Lorundrostat Driven by Successful Trials and Future Potential - TipRanks

May 13, 2025

May 13, 2025

Mineralys Therapeutics (MLYS) Receives Buy Rating Reiteration fr - GuruFocus

May 13, 2025

May 13, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025

May 13, 2025

Strong Financial Position and Promising Clinical Results Support Buy Rating for Mineralys Therapeutics - TipRanks

May 13, 2025

May 13, 2025

Optimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data Releases - TipRanks

May 13, 2025

May 13, 2025

Mineralys Therapeutics Reports Strong Trial Results and Financial Growth - TipRanks

May 13, 2025

May 12, 2025

Earnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock rises - Investing.com

May 12, 2025

May 12, 2025

Mineralys Therapeutics reports Q1 EPS (79c), consensus (98c) - TipRanks

May 12, 2025

May 12, 2025

Mineralys Therapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025